9 / 20
Page 26
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
Adipose/Macrophage fatty acid binding protein: A new marker for pro-tumor macrophages
Bing Li
University of Louisville, USA
T
umor associated macrophages (TAMs) play a critical role
in cancer development and progression. However, due
to the heterogeneity of TAMs, it remains a major challenge
to identify clinically-relevant markers for pro-tumor TAMs.
Here, we report that expression of adipocyte/macrophage
fatty acid binding protein (A-FABP) in TAMs promotes breast
cancer progression. While upregulation of A-FABP was
inversely associated with breast cancer survival, deficiency
of A-FABP significantly reduced mammary tumor growth and
metastasis. Furthermore, we demonstrated that the pro-
tumor effect of A-FABP was mediated by TAMs, in particular
in a subset of TAMs with a CD11b+F4/80+MHCII-Ly6C-
phenotype. Mechanistically, A-FABP expression in TAMs
facilitated pro-tumor IL-6/STAT3 signaling through regulation
of NFκB/miR-29b pathway (Figure). Collectively, our results
suggest that A-FABP may represent as a new functional
marker for pro-tumor TAMs. Tumor stroma contains
heterogeneous macrophages with different phenotype and
function, among which A-FABP is highly expressed in the
subset of CD11b+F4/80+MHCII-Ly6C- promoting mammary
tumor growth and metastasis through NFκB/miR-29b/
IL-6 pathway. Thus, A-FABP represents a new functional
marker for pro-tumor macrophages and a novel target for
macrophage-based tumor immunotherapy.
Speaker Biography
Bing Li has completed his PhD in Immunology at Peking University Health Science
Center, Beijing, China in 2004. He has expertise in the areas of obesity, chronic
inflammation and mammary tumor development. His research is focused on dissecting
the role of fatty acid binding proteins in regulation of metabolism and function of
immune cells in different disease models
e:
b.li@louisville.edu